Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.

Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Clack G, Bianco AR; ATAC Trialists' Group.

J Obstet Gynaecol. 2010;30(6):596-604. doi: 10.3109/01443615.2010.492433.

PMID:
20701510
2.

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU; ATAC Trialists' Group.

Lancet Oncol. 2008 Sep;9(9):866-72. doi: 10.1016/S1470-2045(08)70182-7. Epub 2008 Aug 12.

3.

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S.

J Clin Oncol. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787.

PMID:
18165639
4.

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR.

Br J Cancer. 2006 Jun 5;94(11):1604-9.

5.

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G.

Clin Cancer Res. 2006 Jan 15;12(2):577-83.

6.

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G.

Endocr Relat Cancer. 2005 Dec;12(4):1051-8.

7.

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.

De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello GP, De Vita F, Ficorella C, Farris A, Pistillucci G, Gemini M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco AR.

Br J Cancer. 2005 Oct 17;93(8):896-904.

8.

The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.

Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR.

Hum Reprod. 2006 Feb;21(2):545-53. Epub 2005 Oct 6.

PMID:
16210385
9.

Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region.

Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, Scalvenzi M, Salvatore G, Fabbrocini G, Molea G, Bianco AR, Carlomagno C, De Rosa G.

Hum Pathol. 2005 Jul;36(7):724-31.

PMID:
16084940
10.

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.

Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F, Tortora G.

Clin Cancer Res. 2005 Aug 1;11(15):5639-44.

11.

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S.

Clin Cancer Res. 2005 Jul 1;11(13):4741-8.

12.

Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.

Perdonà S, Autorino R, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco AR, Di Lorenzo G.

Lancet Oncol. 2005 May;6(5):295-300.

PMID:
15863377
13.

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.

De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR.

Br J Cancer. 2005 May 9;92(9):1644-9.

14.
15.
16.

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.

De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D'Aprile M, Pistillucci G, Farris A, Sarobba MG, Palazzo S, Manzione L, Adamo V, Palmeri S, Ferraù F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco AR; GOCSI Cooperative Group.

Br J Cancer. 2005 Feb 14;92(3):467-74.

17.

Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.

Di Lorenzo G, De Placido S, Autorino R, De Laurentiis M, Mignogna C, D'Armiento M, Tortora G, De Rosa G, D'Armiento M, De Sio M, Bianco AR, D'Armiento FP.

Prostate Cancer Prostatic Dis. 2005;8(1):54-9.

PMID:
15655565
18.

FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.

Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D'Armiento M, Bianco AR, De Placido S.

Jpn J Clin Oncol. 2004 Dec;34(12):747-50.

PMID:
15640506
19.

Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.

Di Lorenzo G, Pizza C, Autorino R, De Laurentiis M, Marano O, D'Alessio A, Cancello G, Altieri V, Tortora G, Perdonà S, Bianco AR, De Placido S.

Eur Urol. 2004 Dec;46(6):712-6.

PMID:
15548437
20.

The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.

Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR; ATAC Trialists' Group.

Hum Reprod. 2005 Jan;20(1):294-301. Epub 2004 Oct 28.

PMID:
15513977
21.
22.

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.

Clin Cancer Res. 2004 Jul 15;10(14):4858-64.

23.

HER-2/neu receptor in prostate cancer development and progression to androgen independence.

Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, De Placido S.

Tumori. 2004 Mar-Apr;90(2):163-70. Review.

PMID:
15237576
24.

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2004 Jan 15;10(2):784-93.

25.

The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.

Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J, Coibion M, Bianco AR.

BJOG. 2003 Dec;110(12):1099-106.

26.

Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.

Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S.

Tumori. 2003 Jul-Aug;89(4):349-60. Review.

PMID:
14606635
27.

Recombinant IFN-alpha2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells.

Quesada P, Malanga M, Di Meglio S, De Lorenzo S, Fabbrocini A, Garbi C, Bianco AR, Pepe S.

Eur J Cancer. 2003 Sep;39(14):2103-9.

PMID:
12957467
28.

EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells.

Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, Pepe S, Vitale G, Improta S, Tassone P, Venuta S, Bianco AR, Abbruzzese A.

Cell Death Differ. 2003 Feb;10(2):218-29.

29.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

30.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

31.

Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.

De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L, Pettinato G, Petrella G, Bianco AR.

Clin Cancer Res. 2003 Mar;9(3):1039-46.

32.

External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.

Di Lorenzo G, Autorino R, Ciardiello F, Raben D, Bianco C, Troiani T, Pizza C, De Laurentiis M, Pensabene M, D'Armiento M, Bianco AR, De Placido S.

Oncol Rep. 2003 Mar-Apr;10(2):399-404. Review.

PMID:
12579279
33.

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F.

Clin Cancer Res. 2003 Feb;9(2):866-71.

34.

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F.

Clin Cancer Res. 2002 Nov;8(11):3438-44.

35.

Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.

Carlomagno C, Lauria R, De Laurentiis M, Arpino G, Massarelli E, Ferrara C, Milano A, Vernaglia Lombardi A, Costanzo R, Catalano G, Bianco AR, De Placido S.

Oncology. 2002;63(3):219-25.

PMID:
12381900
36.

Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2002 Oct;8(10):3250-8.

37.

p53 expression is decreased in primary breast carcinomas with microsatellite instability.

Pizzi C, Panico L, De Marchis L, Mastranzo P, Di Maio M, D'Amico C, Limite G, Pettinato G, Cocozza S, Bianco AR, Contegiacomo A.

Breast Cancer Res Treat. 2002 Jun;73(3):257-66.

PMID:
12160331
38.

Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.

Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Martignetti A.

Am J Clin Oncol. 2002 Jun;25(3):224-6.

PMID:
12040276
39.

Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).

Pizzi C, Caraglia M, Cianciulli M, Fabbrocini A, Libroia A, Matano E, Contegiacomo A, Del Prete S, Abbruzzese A, Martignetti A, Tagliaferri P, Bianco AR.

Anticancer Res. 2002 Mar-Apr;22(2A):727-32.

PMID:
12014643
40.

Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer.

Tortora G, Ciardiello F, Damiano V, De Laurentiis M, Matano E, Pepe S, Pensabene M, Catalano G, De Placido S, Bianco AR.

Ann Oncol. 2002 Mar;13(3):392-8.

PMID:
11996469
41.

ZD1839 (Iressa): preclinical studies and pharmacology.

Ciardiello F, Tortora G, De Placido S, Bianco AR.

Tumori. 2002 Jan-Feb;88(1 Suppl 1):S155-7. No abstract available.

PMID:
11989913
42.

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.

Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G.

Int J Cancer. 2002 Mar 20;98(3):463-9.

43.
44.

Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.

Galietta A, Pizzi C, Pettinato G, Limite G, Sgambato A, Lamberti M, Muraro R, Formisano C, Pensabene M, Bianco AR, Mariani-Costantini R, Contegiacomo A.

Oncol Rep. 2002 Jan-Feb;9(1):135-40.

PMID:
11748471
45.

Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.

Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2001 Aug;7(8):2537-44.

46.

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J, Bianco AR, Tortora G.

Int J Cancer. 2001 Jul 15;93(2):172-8.

47.

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2001 May;7(5):1459-65.

48.

Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.

De Placido S, Tramontana S, Ferrari E, De Matteis A, Lauria R, Perrone F, Bianco AR, Gallo C, Ricchi P, De Placido G, Pignata S; GCTO (Gruppo Campano Sui Tumori Dell'Ovaio).

Anticancer Res. 2000 Sep-Oct;20(5C):4023-9.

PMID:
11268496
49.

New perspectives in the treatment of breast cancer. Introduction.

Bianco AR.

Tumori. 2000 Sep-Oct;86(5 Suppl 1):S3. No abstract available.

PMID:
11212854
50.

Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2000 Nov;6(11):4343-50.

Supplemental Content

Loading ...
Support Center